WHEN SEIZURES START I've got this I've got this

VALTOCO® (diazepam nasal spray) is indicated for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (ie, seizure clusters, acute repetitive seizures) that are distinct from a patient's usual seizure pattern in patients with epilepsy 6 years of age and older.1

Discover VALTOCO

To prescribe VALTOCO to your patients, you can e-prescribe or send a VALTOCO prescription form to Maxor Specialty Pharmacy

Stay up to date with all the benefits and resources VALTOCO has to offer. With our comprehensive form you can:

Connect with VALTOCO sales representative

Connect with a VALTOCO sales representative

VALTOCO office starter kit

Order an Office Starter Kit, including demo sprayer

VALTOCO virtual training

Request virtual administration training

HERITAGE AND INNOVATION WORK TOGETHER1-3

VALTOCO combines the trusted history of diazepam with the novel formulation technology of Intravail®.1,3,4 Diazepam has been recognized as a safe and effective seizure treatment for more than 50 years and has been prescribed as a seizure rescue treatment for nonmedical care partner use for more than 20 years.1,3,5,6 Additionally, Intravail® is designed to increase bioavailability and reliability of drug delivery for nasal administration.2,7

Intravail® logo

VALTOCO USES THE SCIENCE OF INTRAVAIL®

The science of Intravail® facilitates drug absorption across the nasal mucosa and increases permeability of cell membranes.2,7 And the innovative technology of Intravail®—which can be utilized via the oral, buccal, dermal, and intranasal routes of administration—provides advantages, including application to a wide range of molecules, solubility of water and oils, and more.

LEARN EVEN MORE ABOUT VALTOCO—WATCH THIS CLINICAL WEBINAR

 

VALTOCO REPLACEMENT PROGRAM

The VALTOCO replacement program ensures that patients can receive replacement product if they don't use their VALTOCO before it expires. The program is offered through Maxor Specialty Pharmacy at no cost to patients or third-party payers.

Contact Maxor for more information.

1-866-629-6779

myNEURELIS™ is a flexible program that allows patients and care partners to personally select their desired support services—from help checking their VALTOCO insurance coverage, to providing financial assistance to those who qualify, access to nurse educators, education, and more.

LEARN MORE

 

Neurelis is focused on developing therapies for disorders involving the central nervous system. The company is dedicated to addressing unmet needs in patient care with therapies that have the potential to change the lives of patients, care partners, and healthcare providers.

IMPORTANT SAFETY INFORMATION, INCLUDING BOXED WARNING 

RISK FROM CONCOMITANT USE WITH OPIOIDS

Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death.

  • Reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate
  • Limit dosages and durations to the minimum required
  • Follow patients for signs and symptoms of respiratory depression and sedation

Contraindications: VALTOCO is contraindicated in patients with:

  • Known hypersensitivity to diazepam
  • Acute narrow-angle glaucoma

Central Nervous System (CNS) Depression

Benzodiazepines, including VALTOCO, may produce CNS depression. Caution patients against engaging in hazardous activities requiring mental alertness, such as operating machinery, driving a motor vehicle, or riding a bicycle, until the effects of the drug, such as drowsiness, have subsided, and as their medical condition permits.

The potential for a synergistic CNS-depressant effect when VALTOCO is used with alcohol or other CNS depressants must be considered, and appropriate recommendations made to the patient and/or care partner.

Suicidal Behavior and Ideation

Antiepileptic drugs (AEDs), including VALTOCO, increase the risk of suicidal ideation and behavior. Patients treated with any AED for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or unusual changes in mood or behavior. Advise patients and caregivers to be alert for these behavioral changes and to immediately report them to a healthcare provider.

Glaucoma

Benzodiazepines, including VALTOCO, can increase intraocular pressure in patients with glaucoma. VALTOCO may only be used in patients with open-angle glaucoma only if they are receiving appropriate therapy. VALTOCO is contraindicated in patients with narrow-angle glaucoma.

Risk of Serious Adverse Reactions in Infants due to Benzyl Alcohol Preservative

VALTOCO is not approved for use in neonates or infants. Serious and fatal adverse reactions, including “gasping syndrome,” can occur in neonates and low-birth-weight infants treated with benzyl alcohol-preserved drugs, including VALTOCO. The “gasping syndrome” is characterized by central nervous system depression, metabolic acidosis, and gasping respirations. The minimum amount of benzyl alcohol at which serious adverse reactions may occur is not known.

Adverse Reactions

The most common adverse reactions (at least 4%) were somnolence, headache, and nasal discomfort.

Diazepam, the active ingredient in VALTOCO, is a Schedule IV controlled substance.

To report SUSPECTED ADVERSE REACTIONS, contact Neurelis, Inc. at 1-866-696-3873 or FDA at 1-800-FDA-1088 (www.fda.gov/medwatch).

Please read full Prescribing Information, including Boxed Warning, for additional important safety information.

Indication

VALTOCO® (diazepam nasal spray) is indicated for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (ie, seizure clusters, acute repetitive seizures) that are distinct from a patient’s usual seizure pattern in patients with epilepsy 6 years of age and older.

IMPORTANT SAFETY INFORMATION

RISK FROM CONCOMITANT USE WITH OPIOIDS

Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death.

  • Reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate
  • Limit dosages and durations to the minimum required
  • Follow patients for signs and symptoms of respiratory depression and sedation

Contraindications: VALTOCO is contraindicated in patients with:

  • Known hypersensitivity to diazepam
  • Acute narrow-angle glaucoma

Central Nervous System (CNS) Depression

Benzodiazepines, including VALTOCO, may produce CNS depression. Caution patients against engaging in hazardous activities requiring mental alertness, such as operating machinery, driving a motor vehicle, or riding a bicycle, until the effects of the drug, such as drowsiness, have subsided, and as their medical condition permits.

The potential for a synergistic CNS-depressant effect when VALTOCO is used with alcohol or other CNS depressants must be considered, and appropriate recommendations made to the patient and/or care partner.

Suicidal Behavior and Ideation

Antiepileptic drugs (AEDs), including VALTOCO, increase the risk of suicidal ideation and behavior. Patients treated with any AED for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or unusual changes in mood or behavior. Advise patients and caregivers to be alert for these behavioral changes and to immediately report them to a healthcare provider.

Glaucoma

Benzodiazepines, including VALTOCO, can increase intraocular pressure in patients with glaucoma. VALTOCO may only be used in patients with open-angle glaucoma only if they are receiving appropriate therapy. VALTOCO is contraindicated in patients with narrow-angle glaucoma.

Risk of Serious Adverse Reactions in Infants due to Benzyl Alcohol Preservative

VALTOCO is not approved for use in neonates or infants. Serious and fatal adverse reactions, including “gasping syndrome,” can occur in neonates and low-birth-weight infants treated with benzyl alcohol-preserved drugs, including VALTOCO. The “gasping syndrome” is characterized by central nervous system depression, metabolic acidosis, and gasping respirations. The minimum amount of benzyl alcohol at which serious adverse reactions may occur is not known.

Adverse Reactions

The most common adverse reactions (at least 4%) were somnolence, headache, and nasal discomfort.

Diazepam, the active ingredient in VALTOCO, is a Schedule IV controlled substance.

To report SUSPECTED ADVERSE REACTIONS, contact Neurelis, Inc. at 1-866-696-3873 or FDA at 1-800-FDA-1088 (www.fda.gov/medwatch).

Please read full Prescribing Information, including Boxed Warning, for additional important safety information.

References: 1. VALTOCO® (diazepam nasal spray) Prescribing Information. Neurelis, Inc. 2. Maggio ET. Intravail®: highly effective intranasal delivery of peptide and protein drugs. Expert Opin Drug Deliv. 2006;3(4):529-539. 3. Parsonage MJ, Norris JW. Use of diazepam in treatment of severe status epilepticus. Br Med J. 1967;3:85-88. 4. Data on file. REF-00208. Neurelis, Inc. 5. Sanchez Fernandez I, Gainza-Lein M, Loddenkemper T. Nonintravenous rescue medications for pediatric status epilepticus: a cost-effectiveness analysis. Epilepsia. 2017;58(8):1349-1359. 6. Drugs@FDA: FDA approved drug products. Approval dates, history, and labels; reviews for NDA 020648. Original approvals. 7. Maggio ET, Pillion DJ. High efficiency intranasal drug delivery using Intravail® alkylsaccharide absorption enhancers. Drug Deliv Transl Res. 2013;3:16-25.